Core Insights - OneMedNet Corporation has demonstrated significant engagement and commercial traction at the RSNA Annual Meeting, indicating strong interest from hospitals, imaging centers, and life sciences innovators in its iRWD™ platform powered by Palantir Foundry [1][2][5] Company Overview - OneMedNet is a leading provider of regulatory-grade, AI-ready Real-World Data (RWD) networks, leveraging over 2,130 healthcare sites to deliver insights that drive innovation in healthcare [6] - The company focuses on providing high-quality, multimodal datasets that support healthcare providers and life sciences organizations in research and product development [5][6] Market Validation - The RSNA 2025 event validated OneMedNet's strategy amid rising demand for regulatory-grade RWD, with healthcare providers expressing a strong interest in utilizing their clinical data assets [2][3] - Life sciences companies and AI developers showed keen interest in the next-generation iRWD™ platform, highlighting its capabilities in providing large-scale, high-fidelity datasets and AI-enabled cohort discovery [4][5] Strategic Partnerships - Healthcare providers are looking for reliable and low-effort ways to engage in healthcare innovation and research, while life sciences organizations require scalable datasets to accelerate product development [5] - OneMedNet's efficient deployment model and opportunities for compliant data sharing were noted as key advantages for potential partners [3][5]

Core Insights - American Rebel Holdings, Inc. has formed a strategic distribution partnership with Ace Distributing, enhancing its presence in South Central Pennsylvania and supporting its "distribution-first" growth strategy [1][2][12] - Ace Distributing, a family-owned wholesaler with over 75 years of experience, will distribute American Rebel Light Beer across 11 counties, leveraging its network of more than 1,400 retail accounts [1][3][9] - The partnership marks American Rebel's fifth top-tier distributor in Pennsylvania, contributing to a rapid expansion in distribution and brand visibility [1][2][8] Company Overview - American Rebel Holdings, Inc. is positioned as "America's Patriotic Brand," focusing on beverages and other patriotic lifestyle products [11][12] - The company emphasizes a values-driven marketing approach, appealing to conservative audiences with its branding and product identity [7][9] Product Details - American Rebel Light Beer is a premium all-natural light lager with a profile of approximately 100 calories, 3.2g carbs, and 4.3% ABV per 12 oz [7][8] - The beer is marketed as "America's Patriotic Beer," aligning with themes of faith, freedom, and patriotism [7][10] Distribution Strategy - The partnership with Ace Distributing is part of a broader strategy to build a national distribution network, with recent additions of multiple distributors in Pennsylvania [2][12] - American Rebel Light Beer has secured distribution in 17 states and aims for further expansion through partnerships with top-tier wholesalers [8][12] Ace Distributing Profile - Ace Distributing has a strong reputation in the industry, recognized for its service and innovative marketing strategies, including community engagement initiatives [9][10] - The company has been nominated for multiple industry awards, reflecting its commitment to quality and excellence in distribution [9][10]

Core Insights - Sanara MedTech Inc. plans to launch OsStic Synthetic Injectable Structural Bio-Adhesive in the U.S. market in Q1 2027, following FDA clearance [1][2] - OsStic has received Breakthrough Device Designation from the FDA, indicating its potential to improve treatment for serious conditions [2] - The product is expected to be the first bone bioadhesive in the U.S. utilizing phosphoserine, α-TCP, and calcium silicate, offering significant advantages over traditional methods [2][3] Product Development and Regulatory Milestones - Sanara and Biomimetic Innovations Ltd (BMI) have achieved significant milestones in product development, clinical trials, and regulatory processes throughout 2025 [3] - The U.S. Patent and Trademark Office granted a patent for OsStic, ensuring protection of its key ingredients and applications until at least 2037 [3][6] - The partnership between Sanara and BMI includes an exclusive license and distribution agreement, enhancing Sanara's market position in orthopedic care [5][6] Market Need and Innovation - OsStic addresses critical limitations in current provisional fixation techniques, providing forty times stronger bonding than traditional calcium phosphate bone cement [2][3] - The product aims to meet the unmet clinical needs in complex joint reconstruction, offering a paradigm shift in treating previously non-repairable fractures [3] - Sanara's commitment to innovation is reflected in its collaboration with BMI to introduce OsStic as a new standard in bone bioadhesives [4]

Core Points - Quorum Information Technologies Inc. has completed a statutory plan of arrangement, resulting in the acquisition of all issued and outstanding common shares at a price of $0.80 per share in cash by 2745122 Alberta Inc., an affiliate of Valsoft Corporation Inc. [1] - The company expects to delist its common shares from the TSX Venture Exchange on or about December 10, 2025, pending final approval [2]. Company Overview - Quorum is a North American SaaS software and services company that provides essential enterprise solutions for automotive dealerships and Original Equipment Manufacturers [3]. - The company offers various products, including a Dealership Management System (DMS), DealerMine CRM, Autovance, Accessible Accessories, and VINN Automotive, which enhance dealership operations and customer satisfaction [5].

Core Insights - KeepZone AI Inc. will make a first installment payment of $200,000 to Scanary Ltd. by December 11, 2025, as part of a $1 million distribution agreement [1][2] - The agreement includes exclusive rights for KeepZone to market and sell Scanary's AI-radar screening systems to stadium operators in Israel for an initial six-month period, which can extend if sales are made [3][4] - This partnership is expected to enhance KeepZone's position in the homeland security sector and create new growth opportunities [4] Financial Details - The total consideration under the distribution agreement is $1 million, with the first installment being $200,000 [2] - The payment is part of a strategic partnership that indicates strong momentum between KeepZone and Scanary [2] Strategic Partnership - The exclusivity granted to KeepZone for marketing Scanary's technology in Israeli stadiums is in addition to existing rights in Canada, Germany, and the UAE [3] - The technology can screen up to 25,000 people per hour without requiring them to stop, which is significant for high-demand venues [3] Company Overview - Jeffs' Brands Ltd. operates as a data-driven e-commerce company on the Amazon Marketplace, focusing on transforming products into market leaders [5]

Core Insights - VisionWave Holdings, Inc. has initiated the patent-application process for its Argus platform, which is a space-enabled, AI-driven counter-unmanned aircraft system (C-UAS) [1][2] - The company aims to secure intellectual property protection for key technologies related to Argus, including its core system architecture and enabling technologies [2][3] - VisionWave plans to follow up with additional patent applications to cover further aspects of the Argus technology stack, enhancing its competitive position in the counter-drone defense market [3][4] Company Strategy - The company has engaged intellectual-property counsel to prepare provisional patent applications focused on various components of the Argus platform, such as the SkyWeave™️ high-frequency AI-driven communications backbone and drone detection methods [2][3] - VisionWave's strategy includes structuring Argus as a multi-patent platform to secure a defensible position around technologies essential for next-generation wide-area counter-drone defense [4] Technology Focus - Key technologies being targeted for patent protection include HF-enabled sensor fusion, multi-layer decision and control logic, and secure key-exchange mechanisms optimized for contested environments [3] - The Argus platform aims to deliver scalable capabilities for the detection, classification, tracking, and defeat of emerging aerial threats, contributing to national security and critical infrastructure protection [5]

Core Insights - Journey Medical Corporation announced successful results from a Phase 1 clinical trial for Emrosi, indicating it can be safely used for up to 16 weeks without significant safety issues [1][2] - Emrosi is FDA-approved for treating inflammatory lesions of rosacea in adults, with a focus on maintaining normal microbiota and avoiding antibiotic resistance [2][5] Company Overview - Journey Medical Corporation is a commercial-stage pharmaceutical company focused on marketing FDA-approved prescription products for dermatological conditions [8] - The company currently markets eight branded FDA-approved prescription drugs aimed at treating common skin conditions [8] Clinical Trial Details - The Phase 1 clinical trial (DFD-29-CD-006) was a multicenter, randomized, double-blind, placebo-controlled study involving 60 healthy adults [2] - The trial achieved all primary microbiological endpoints, showing no significant changes in skin, gastrointestinal, or vaginal microbiota [5] - No significant safety issues were reported during the study, reinforcing the treatment's tolerability [2][5] Rosacea Background - Rosacea is a chronic inflammatory skin condition affecting over 16 million Americans and approximately 415 million people worldwide [3] - The condition significantly impacts patients' self-confidence and social interactions, with many reporting adverse effects on professional life [3]

HOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 727,969 shares of common stock of the Company originally issued in February 2025 at an ex ...

Core Insights - PharmAla Biotech Holdings Inc. has successfully completed the release testing of its first Australian-made batch of LaNeo™ MDMA 40mg capsules, marking a significant milestone for the company [1] - The company is set to enter an active production schedule for 2026, which includes the development of 20mg capsules and the manufacture of ALA-002 capsules [2] - PharmAla has completed its first delivery of Australian-made product to the Orygen Institute, supporting a Phase 3 Trial for social anxiety in autistic youth, concluding its contract with Orygen [3] Company Overview - PharmAla Biotech Holdings Inc. focuses on the research, development, and manufacturing of MDXX class molecules, including MDMA, and aims to alleviate the global backlog of clinical-grade MDMA for clinical trials and commercial sales [4] - The company is recognized as the only provider of clinical-grade MDMA for patient treatments outside of clinical trials and has completed proof-of-concept research into several drug candidates, including ALA-002 [4] - PharmAla operates under a "regulatory first" principle, emphasizing the importance of strong relationships with regulators in the psychedelics industry [4]

Martela Corporation, inside information, 10.12.2025, at 15:30 The development of revenue and order intake has been weaker than expected during the current quarter on Martela's key market areas. The margin development on projects and deliveries has continued to be positive in the second half of the year, but the margin levels have developed slightly below previous expectations. Due to these reasons, Martela is lowering its full-year profit forecast. New guidance for 2025: Martela Group's full-year 2025 reven ...